|
 |
| |
|
ŰƮ·ç´ÙÁÖ(Æèºê·Ñ¸®ÁÖ¸¿,À¯ÀüÀÚÀçÁ¶ÇÕ) 4mL Keytruda Inj.
|
|
Àü¹®ÀǾàǰ | ±Þ¿© | ½Å¾à
|
|
¼öÀÔÀǾàǰ
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
Àü¹®/ÀÏ¹Ý |
Àü¹®
|
|
|
|
| Åõ¸íÇϰųª ¾à°£ À¯¹é±¤ÀÇ, ¹«»ö ¶Ç´Â ¿¶Àº ³ë¶õ»öÀÇ ¾×ü°¡ ¹«»öÅõ¸íÇÑ ¹ÙÀ̾˿¡ µç ÁÖ»çÁ¦ |
|
|
|
|
|
Á¦Á¶È¸»ç |
Çѱ¹¿¥¿¡½ºµð(ÁÖ)
|
ÆÇ¸Åȸ»ç |
Çѱ¹¿¥¿¡½ºµð(ÁÖ)
|
Çã°¡Á¤º¸ |
Á¤»ó
(2015.03.20)
|
BIT ¾àÈ¿ºÐ·ù |
´ÜŬ·ÐÇ×ü Ç×¾ÏÁ¦(Monoclonal antibodies)
|
º¹ÁöºÎºÐ·ù |
421[Ç׾ǼºÁ¾¾çÁ¦ ] |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå |
655501901 \2,103,620 ¿ø/4mL/º´(2024.07.01)(ÇöÀç¾à°¡)\2,107,642 ¿ø/4mL/º´(2022.03.01) (º¯°æÀü¾à°¡)
|
|
|
ATCÄÚµå |
pembrolizumab / L01FF02 |
NDCÄÚµå |
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
|
¼ººÐ / ÇÔ·® |
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]

|
÷°¡Á¦ |
¹é´ç,
ÁÖ»ç¿ë¼ö,
Æú¸®¼Ò¸£º£ÀÌÆ® 80,
L-È÷½ºÆ¼µò,
L-È÷½ºÆ¼µò¿°»ê¿°Àϼöȹ°
|
|
|
|
|
 |
|
|
|
|
|
| Ç× ¸ñ |
³» ¿ë |
|
|
| |
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-10-07 |
|
|
|
|
| |
|
|
|